Prescribing Information for ▼PAXLOVID (nirmatrelvir / ritonavir) can be found here: Great Britain and Northern Ireland. Adverse event reporting information can be found at the bottom of the page. Please note, there are differences between the SmPC for Northern Ireland and the SmPC for Great Britain. Please refer to the appropriate SmPC depending on where you are based.
Paxlovid has a Conditional Marketing Authorisation in Great Britain. A Conditional Marketing Authorisation means that further evidence on this medicinal product is awaited. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year and the product information will be updated as necessary.
Paxlovid is now the only NICE-recommended treatment option for eligible select adult patient cohorts, and remains first line for eligible adult patients who do not need supplemental oxygen and are at increased risk of progression to severe COVID-19 as defined by the Independent Advisory Group Report.1,3 A one page summary of the high risk eligible adult cohorts is available here.
| NICE recommended eligible cohorts for COVID-19 treatment: | ||
|---|---|---|
| Implementation: 13th June 2024 | Implementation: 1st June 2025 | |
| PAXLOVID is the only treatment option:1 | People aged > 85 years | Aged > 70 years |
People resident in a care home or already hospitalised and:
|
Body mass index (BMI) of >35 kg/m2 | |
| People on the organ transplant waiting list | Diabetes | |
| People with end-stage heart failure who have long-term ventricular assistance devices | Heart failure | |
| PAXLOVID is recommended first line:1 |
Patients as defined by the Independent Advisory Group Report in Section 5 of NICE TA878* who are at greatest risk of progression to severe disease e.g. Immune mediated inflammatory disorders, certain cancers, immune deficiencies etc.1,4 Visit the report for full details on which patients are considered to be at greatest risk of progression to severe disease. |
|---|---|
•Sotrovimab is recommended second line if Paxlovid (nirmatrelvir/ritonavir) is contraindicated or unsuitable and if the company provides it according to the commercial arrangement1 |
The decision to treat and choice of treatment is based on the individual patient’s eligibility criteria, clinical circumstances and is ultimately at the discretion of the individual prescriber. Please refer to the relevant SmPC (GB or NI)5,6 before making any prescribing decisions.
The staged rollout is due to NHS England's ambition to potentially protect the eligible highest risk adult patients while ensuring equitable access to treatment.1
Set up a PfizerPro account to access further materials and resources, and receive communication about medicines and vaccines promoted by Pfizer.
Learn about PAXLOVID dosing, potential drug interactions, and how to prescribe.
Summary of the high risk adult patients who may be eligible for COVID-19 treatment.
Explore downloadable materials to further support both you and your patients.
Explore more videos
Watch short educational key-opinion-leader (KOL) videos from Healthcare Professionals on their experience in managing patients at risk of severe COVID-19.
Adverse Events
Adverse Events should be reported. Reporting forms and information can be found at https://coronavirus-yellowcard.mhra.gov.uk/ or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024